ANIK Anika Therapeutics Inc.

56.69
-0.33  -1%
Previous Close 57.02
Open 56.95
Price To book 3.40
Market Cap 830986964
Shares 14,658,440
Volume 70,501
Short Ratio 15.84
Av. Daily Volume 96,210

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 2014
Monovisc
Osteoarthritis
Additional Phase 3 trial commenced enrollment - May 25 2017. Trial to be completed in 2018.
Cingal
Osteoarthritis

Latest News

  1. Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
  2. ETFs with exposure to Anika Therapeutics, Inc. : August 15, 2017
  3. Anika (ANIK) Grows in Orthopedic Medicines on Positive Data
  4. Edited Transcript of ANIK earnings conference call or presentation 27-Jul-17 1:00pm GMT
  5. Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee
  6. Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017
  7. Anika Announces Appointment of Joseph Darling as President
  8. Investor Network: Anika Therapeutics, Inc. to Host Earnings Call
  9. Anika posts 2Q profit
  10. Anika Reports Strong Second Quarter 2017 Financial Results
  11. Anika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : July 26, 2017
  12. Anika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints
  13. The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics
  14. Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
  15. Anika pays former medical chief $350K to thwart possible lawsuit
  16. 4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings
  17. Anika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26
  18. Anika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : July 12, 2017
  19. ETFs with exposure to Anika Therapeutics, Inc. : July 11, 2017
  20. New Strong Sell Stocks for July 11th

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171014563
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17990049
  3. 8-K - Current report 17984527
  4. 8-K - Current report 17982879
  5. 8-K - Current report 17965618
  6. S-8 - Securities to be offered to employees in employee benefit plans 17954480
  7. 8-K - Current report 17918559
  8. 8-K/A [Amend] - Current report 17818373
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814801
  10. 8-K - Current report 17809115